Lion's Mane for Neuropathy
Lion's Mane has not been shown to help peripheral neuropathy in people. Evidence is limited to laboratory and animal studies, with no human clinical trials, so it should not replace established neuropathy treatment.
Why this grade7-layer evidence engine
This claim is graded Unverified (Insufficient Evidence) because every study on Lion's Mane for nerve damage is preclinical. A rat peroneal nerve-crush model found faster functional recovery and better axon regeneration, roughly comparable to the mecobalamin control but with no statistical test reported (PMID 21941586). Two further studies showed only neurite outgrowth and axonal regrowth in cells via NGF-related signaling (PMID 25159861, PMID 30570422). These describe a biological mechanism, not a clinical effect.
Critically, no human randomized trial, meta-analysis, or systematic review has tested Lion's Mane on neuropathic pain, nerve conduction, or symptom scores. The only recent double-blind trial (PMID 40276537) studied cognition and mood in healthy adults, not neuropathy, and found no significant overall benefit, so it does not support this use.
Regulators and clinics offer no backing. The US FDA never completed its review of a Hericium erinaceus food-substance notice and has issued warning letters to firms marketing it for neurologic disease; EFSA has botanical claims on hold; and NIH ODS, Mayo, Cleveland Clinic, and Harvard Health do not address it for neuropathy. The neurotrophic rationale is plausible but clinically unproven.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.453
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism)，不足以下結論
- tier_strict_requirement_check — C 級條件未達 (需 E1-E8；實際 E10 僅機轉)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status